Emergent BioSolutions, Inc. has initiated the non-clinical efficacy study to demonstrate that BioThrax (Anthrax Vaccine Adsorbed) manufactured at large scale at its new facility, is comparable to BioThrax currently manufactured at its approved facility. Data from this study will be used to support licensure of the new facility. Both facilities are located on Emergent’s Lansing, MI campus. BioThrax is the only vaccine licensed by the U.S. FDA for the prevention of anthrax disease.   The randomize...